• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALCON RESEARCH, LLC - HUNTINGTON ACRYSOF IQ VIVITY EXTENDED VISION IOL; INTRAOCULAR LENS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALCON RESEARCH, LLC - HUNTINGTON ACRYSOF IQ VIVITY EXTENDED VISION IOL; INTRAOCULAR LENS Back to Search Results
Model Number DFT015
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Visual Disturbances (2140); Insufficient Information (4580)
Date of Event 06/18/2024
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
A product was not returned for analysis.Complaint history and product history records were reviewed and documentation indicated the product met release criteria.Root cause has not been identified.The manufacturer internal reference number is: (b)(4).
 
Event or Problem Description
A health care professional reported with a description of explantation of the lens.Additional information was requested.
 
Additional Manufacturer Narrative
Correction information was provided in b.3.Additional information was provided in a.2., b.5., b.6., b.7., d.6.A., d.6.B., d.10.The manufacturer internal reference number is: (b)(4).
 
Event or Problem Description
Additional information was received as the patient expressed dissatisfaction with her lenses despite an objectively successful surgical outcome.Over several months, she continued to report severe glare and dysphotopsia.Due to these persistent symptoms, the lenses were recently explanted and replaced with lenses from the same manufacturer but with a different diopter.Following the replacement, there have been no further adverse impacts on the patient.There are two medical device reports associated with this patient.This report is associated with the left eye.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ACRYSOF IQ VIVITY EXTENDED VISION IOL
Common Device Name
INTRAOCULAR LENS
Manufacturer (Section D)
ALCON RESEARCH, LLC - HUNTINGTON
246 kyle lane
huntington WV 25702
Manufacturer (Section G)
ALCON RESEARCH, LLC - HUNTINGTON
246 kyle lane
huntington WV 25702
Manufacturer Contact
jonathan schlech
6201 south freeway
mail stop ab2-6
fort worth, TX 76134
8007579780
MDR Report Key23100877
Report Number1119421-2025-02531
Device Sequence Number9225961
Product Code POE
UDI-Device Identifier00380652421263
UDI-Public(01)00380652421263(17)280731(11)230803(10)15691398
Combination Product (Y/N)N
Initial Reporter CountryGM
PMA/510(K) Number
P930014
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2024
Device Explanted Year2025
Reporter Type Manufacturer
Report Source Foreign,Health Professional,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 01/12/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Model NumberDFT015
Device Catalogue NumberDFT015.215
Device Lot Number15691398
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Follow-Up
Initial Date Received by Manufacturer 08/27/2025
Supplement Date Received by Manufacturer12/18/2025
Initial Report FDA Received Date09/19/2025
Supplement Report FDA Received Date01/12/2026
Date Device Manufactured08/03/2023
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
CLAREON IOL; MONARCH III IOL DELIVERY SYSTEM, CARTRIDGE D; MONARCH III IOL DELIVERY SYSTEM, INJECTOR; OVD: ZEISS VISTHESIA 1%
Outcome Attributed to Adverse Event Required Intervention;
Patient Age70 YR
Patient SexFemale
-
-